Serophene: Clinically Proven Ovulation Induction Therapy
Serophene
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 2.92 $ | 87.75 $ (0%) | 🛒 Add to cart |
| 60 | 2.28 $ | 175.50 $ 136.89 $ (22%) | 🛒 Add to cart |
| 90 | 2.07 $ | 263.25 $ 186.03 $ (29%) | 🛒 Add to cart |
| 120 | 1.96 $ | 351.00 $ 235.17 $ (33%) | 🛒 Add to cart |
| 180 | 1.85 $ | 526.50 $ 333.45 $ (37%) | 🛒 Add to cart |
| 270 | 1.78 $ | 789.75 $ 480.87 $ (39%) | 🛒 Add to cart |
| 360 | 1.75 $
Best per pill | 1053.00 $ 628.29 $ (40%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | 0.62 $ | 56.16 $ (0%) | 🛒 Add to cart |
| 120 | 0.58 $ | 74.88 $ 70.20 $ (6%) | 🛒 Add to cart |
| 180 | 0.55 $ | 112.32 $ 98.28 $ (12%) | 🛒 Add to cart |
| 270 | 0.52 $ | 168.48 $ 140.40 $ (17%) | 🛒 Add to cart |
| 360 | 0.51 $
Best per pill | 224.64 $ 182.52 $ (19%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | 1.56 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 60 | 1.21 $ | 93.60 $ 72.54 $ (23%) | 🛒 Add to cart |
| 90 | 1.09 $ | 140.40 $ 98.28 $ (30%) | 🛒 Add to cart |
| 120 | 1.04 $ | 187.20 $ 125.19 $ (33%) | 🛒 Add to cart |
| 180 | 0.99 $ | 280.80 $ 177.84 $ (37%) | 🛒 Add to cart |
| 270 | 0.95 $ | 421.20 $ 256.23 $ (39%) | 🛒 Add to cart |
| 360 | 0.93 $
Best per pill | 561.60 $ 334.62 $ (40%) | 🛒 Add to cart |
Synonyms | |||
Serophene (clomiphene citrate) is a first-line oral fertility medication specifically designed to stimulate ovulation in women experiencing anovulation or oligo-ovulation. As a selective estrogen receptor modulator (SERM), it works by blocking estrogen receptors in the hypothalamus, prompting the pituitary gland to increase secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This hormonal cascade promotes follicular development and maturation, ultimately leading to ovulation. With decades of clinical use and extensive research supporting its efficacy, Serophene remains a cornerstone treatment in reproductive endocrinology for appropriately selected patients.
Features
- Active ingredient: clomiphene citrate 50 mg
- Administration: oral tablet
- Mechanism: selective estrogen receptor modulator (SERM)
- Bioavailability: approximately 85-90% following oral administration
- Half-life: 5-7 days
- Metabolism: hepatic via CYP2D6 and CYP3A4
- Excretion: primarily fecal (approximately 42-48%), with urinary elimination of metabolites
- Pregnancy category: X (contraindicated in pregnancy)
Benefits
- Effectively induces ovulation in approximately 80% of appropriately selected anovulatory women
- Non-invasive oral administration compared to injectable fertility medications
- Established safety profile with decades of clinical use and research
- Cost-effective first-line treatment option for ovulation induction
- Enables timed intercourse or intrauterine insemination cycles
- Multiple evidence-based dosing protocols available for individualized treatment
Common use
Serophene is primarily indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. The most common applications include management of polycystic ovary syndrome (PCOS)-related anovulation, unexplained infertility with ovulatory factors, and luteal phase defect. Specialists may also utilize clomiphene citrate for ovarian stimulation prior to assisted reproductive technologies, though this application requires careful monitoring. The medication is typically prescribed for women with demonstrated ovarian function but inadequate follicular development and ovulation, confirmed through baseline hormonal assessments and ultrasound evaluation.
Dosage and direction
The initial recommended dosage is 50 mg (one tablet) daily for five days, beginning on day 3, 4, or 5 of the menstrual cycle following spontaneous or progestin-induced withdrawal bleeding. Treatment should be initiated at the lowest effective dose to minimize side effects and multiple gestation risk. If ovulation does not occur at the initial dose, the dosage may be increased to 100 mg daily for five days in subsequent cycles. The maximum recommended daily dose is 150 mg. Dosage adjustments should be made under strict medical supervision with appropriate monitoring through ultrasound follicular tracking and/or serum progesterone measurements 7-9 days after suspected ovulation.
Patients should take Serophene at approximately the same time each day, with or without food, though consistency in administration is recommended. Tablets should be swallowed whole with water and not crushed or chewed. Treatment cycles are typically limited to 3-6 ovulatory cycles maximum due to potential endometrial thinning effects with prolonged use.
Precautions
Before initiating Serophene therapy, comprehensive fertility evaluation must be completed, including assessment of tubal patency, semen analysis, and ovarian reserve testing. Liver function tests should be performed as clomiphene is metabolized hepatically. Patients should be counseled regarding the increased risk of multiple gestation (approximately 5-8%, primarily twins) and the importance of proper timing of intercourse. Ovarian hyperstimulation syndrome (OHSS) occurs in approximately 1% of patients and requires immediate medical attention if symptoms develop.
Regular monitoring through transvaginal ultrasound is essential to assess follicular development and prevent excessive response. Endometrial thickness should be evaluated, as clomiphene may cause endometrial thinning in some patients. Visual disturbances, though rare, require immediate discontinuation and ophthalmologic evaluation. Patients should be advised that long-term continuous use may be associated with slightly increased risk of borderline ovarian tumors.
Contraindications
Serophene is absolutely contraindicated in pregnancy (Category X) and must not be administered if pregnancy is suspected or confirmed. Additional contraindications include liver disease of significant severity, abnormal uterine bleeding of undetermined origin, ovarian cysts not related to polycystic ovarian syndrome, uncontrolled thyroid or adrenal dysfunction, and pre-existing endometrial carcinoma. The medication is contraindicated in patients with known hypersensitivity to clomiphene citrate or any component of the formulation.
Patients with pituitary prolactinoma should not receive Serophene without proper evaluation and management of the underlying condition. The medication is not indicated for use in patients with primary ovarian failure or premature ovarian insufficiency. Male patients should not use Serophene, as it may suppress testosterone production and sperm parameters.
Possible side effects
The most common adverse effects (>10% incidence) include vasomotor flashes (hot flashes) occurring in approximately 10-20% of patients, abdominal discomfort or bloating (approximately 7-15%), and breast tenderness (5-10%). Ovarian enlargement occurs in approximately 5-10% of patients, typically resolving spontaneously after treatment cessation.
Less common side effects (1-10% incidence) include nausea, vomiting, visual disturbances (blurred vision, photophobia, scotomas), headache, and abnormal uterine bleeding. Rare but serious adverse effects (<1% incidence) include ovarian hyperstimulation syndrome, ovarian torsion, and severe visual changes. Most side effects are dose-dependent and reversible upon discontinuation of therapy.
Drug interaction
Serophene may interact with several medication classes. Concomitant use with gonadotropins may potentiate ovarian response and increase risk of OHSS. Tamoxifen and other SERMs may have additive estrogenic/anti-estrogenic effects. CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine) may decrease clomiphene metabolism, potentially increasing adverse effects. CYP3A4 inducers (rifampin, carbamazepine, St. John’s wort) may reduce clomiphene efficacy.
Thyroid hormones and corticosteroids may require dosage adjustments during Serophene therapy. Herbal supplements with estrogenic properties (soy, black cohosh, red clover) may interfere with medication mechanism of action. Always inform healthcare providers of all prescription medications, over-the-counter drugs, and supplements being taken.
Missed dose
If a dose is missed, the patient should take it as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed tablet. Consistency in dosing is important for optimal follicular development, so patients should maintain a regular dosing schedule throughout the five-day treatment course.
If multiple doses are missed during the treatment cycle, the patient should contact their healthcare provider for guidance. The treatment cycle may need to be abandoned and restarted in the subsequent menstrual cycle depending on the timing and number of missed doses.
Overdose
Cases of acute overdose with Serophene are rare due to the relatively high therapeutic index. Reported symptoms of overdose may include nausea, vomiting, vasomotor symptoms, visual disturbances, ovarian enlargement, and abdominal pain. There is no specific antidote for clomiphene citrate overdose. Management should be supportive and symptomatic, including gastric lavage if ingestion occurred within 1-2 hours.
Patients experiencing suspected overdose should seek immediate medical attention. Hospitalization may be required for severe symptoms or massive ingestion. Dialysis is not likely to be effective due to high protein binding and extensive tissue distribution. Ovarian hyperstimulation may occur even with single excessive doses and requires appropriate monitoring.
Storage
Store Serophene tablets at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep the medication in its original container with the lid tightly closed to protect from light and moisture. Do not store in bathroom cabinets where humidity levels fluctuate. Keep out of reach of children and pets.
Do not use Serophene beyond the expiration date printed on the packaging. Properly dispose of any unused medication through medication take-back programs or according to FDA-recommended disposal methods. Do not flush medications down the toilet unless specifically instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Serophene is a prescription medication that should be used only under the supervision of a qualified healthcare provider specializing in reproductive medicine. Individual patient responses may vary, and treatment should be tailored based on comprehensive medical evaluation. The prescribing physician should be consulted for specific medical advice, diagnosis, and treatment recommendations.
Patients should not initiate, discontinue, or change dosage of Serophene without medical supervision. While every effort has been made to ensure accuracy, medical knowledge evolves continuously, and newer information may become available that supersedes current recommendations.
Reviews
Clinical studies consistently demonstrate ovulation rates of 70-80% in appropriately selected anovulatory women, with cumulative pregnancy rates of approximately 30-40% after three treatment cycles. Meta-analyses confirm Serophene’s efficacy as first-line treatment for PCOS-related infertility. Patient satisfaction surveys indicate appreciation for oral administration and established safety profile, though some report bothersome vasomotor symptoms.
Long-term follow-up studies show no significant increase in congenital anomalies compared to general population when conception occurs during properly monitored treatment cycles. Reproductive endocrinologists generally regard Serophene as a valuable tool in fertility treatment when used with appropriate patient selection, dosing, and monitoring protocols.